News Concord Biotech Limited

Equities

CONCORDBIO

INE338H01029

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 09:26:22 12/05/2026 am IST			5-day change	1st Jan Change
1,168.60 ^INR	-2.52%		-1.41%	-13.19%

02/04	Concord Biotech Limited completed the acquisition of Celliimune Biotech Private Limited for 6.6 million.	CI
13/02	Jefferies Adjusts Concord Biotech's Price Target to INR1,170 From INR1,290, Keeps at Hold	MT

All News

Mentions Relevance

02/04	Concord Biotech Limited completed the acquisition of Celliimune Biotech Private Limited for 6.6 million.	CI
13/02	Jefferies Adjusts Concord Biotech's Price Target to INR1,170 From INR1,290, Keeps at Hold	MT
12/02	Concord Biotech Limited, Q3 2026 Earnings Call, Feb 12, 2026
11/02	Concord Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
11/02	Concord Biotech Dec-quarter consol net profit 644.8 million rupees	RE
11/02	Concord Biotech Limited Appoints Paritosh Trivedi as Company Secretary, Compliance Officer, Effective February 11, 2026	CI
24/12	Concord Biotech Limited Announces Resignation of Hina Patel as Company Secretary and Compliance Officer, Effective January 21, 2026	CI
18/12	Concord Biotech Names CFO	MT
18/12	Concord Biotech appoints Raviraj Karia as CFO	RE
18/12	Concord Biotech Limited Appoints Raviraj Karia as Chief Financial Officer, Effective December 18, 2025	CI
18/12	Concord Biotech Limited Appoints Raviraj Karia as Key Managerial Personnel, Effective December 18, 2025	CI
08/12	Concord Biotech says CFO Lalit Sethi to retire	RE
08/12	Concord Biotech's CFO Resigns; Shares Down 3%	MT
08/12	Concord Biotech Limited Announces Retirement of Lalit Sethi as Chief Financial Officer, Effective January 5, 2026	CI
08/12	Concord Biotech Limited Announces Retirement of Lalit Sethi as Key Managerial Personnel, Effective January 5, 2026	CI
17/11	Jefferies Adjusts Concord Biotech's Price Target to INR1,500 From INR1,600, Keeps at Hold	MT
14/11	Concord Biotech Limited, Q2 2026 Earnings Call, Nov 14, 2025
13/11	Concord Biotech posts Sept-quarter consol net profit 635.8 million rupees	RE
13/11	Concord Biotech - approves acquisition of 100% equity in Celliimune Biotech	RE
13/11	Concord Biotech Limited Approvesl to Invest Upto INR 100 Million in Captive Hybrid Solar Power Project for Limbasi Plant	CI
13/11	Concord Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
13/11	Concord Biotech Limited agreed to acquire Celliimune Biotech Private Limited.	CI
08/25/08	Indian Regulator Completes Inspection of Concord Biotech's Gujarat, India Unit	MT
30/25/30	IIFL Starts Concord Biotech at Buy With INR1,970 Price Target	MT
21/25/21	EU-GMP Authorities Conclude Inspection of Concord Biotech's Unit in Limbassi, India; Shares Up 3%	MT